Bausch Hopes B+L Spin-Out Will 'Unlock' The Value Of Eye-Care Business
Bausch Health is paying down its debt with a $630m IPO for its Bausch + Lomb eyecare product business.
You may also be interested in...
The CONCERTO trial will evaluate the company’s SING IMT, an upgrade of its 12-year-old WA IMT device, in up to 100 people in the US with age-related macular degeneration.
Bausch Health shopped Bausch + Lomb IPO at share price between $21 and $24. In trading of nearly 14.4m shares on New York exchange, Bausch + Lomb’s share price stayed above opening $18.50 and reached $20.07 before closing at $20, up 11.11%.
Canadian firm reports Bausch + Lomb full-year and fourth-quarter revenue growth earnings as preparations continue to divest the business. Consumer health led Bausch + Lomb’s segments.